Abstract
We thank Jia et al for their valuable comments regarding our recently published article.1 This prospective study enrolled 259 patients with acute ischemic stroke and found that CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) genotypes had significant impact on clopidogrel response and prognosis of patients with stroke. We have to clarify that the National Institutes of Health Stroke Scale and modified Rankin Scale score in our study were used to evaluate the therapeutic effect of clopidogrel at 3 and 6 months after treatment. In addition to coagulation, platelets also release abundant proinflammatory cytokines that aggravate the pathogenic progress of ischemic injury. Substantial evidence demonstrated that clopidogrel application diminished inflammatory mediators, including C-reactive protein.2 …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
